These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435 [Abstract] [Full Text] [Related]
6. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305 [Abstract] [Full Text] [Related]
7. Indications and management of everolimus after liver transplantation. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R. Transplant Proc; 2009 Oct; 41(6):2172-6. PubMed ID: 19715864 [Abstract] [Full Text] [Related]
8. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence. Castroagudín JF, Molina E, Tomé S, Otero E, Rodríguez M, Varo E. Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410 [Abstract] [Full Text] [Related]
9. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Moya A, Berenguer M, Aguilera V, Juan FS, Nicolás D, Pastor M, López-Andujar R, Rayón M, Orbis F, Mora J, De Juan M, Carrasco D, Vila JJ, Prieto M, Berenguer J, Mir J. Liver Transpl; 2002 Nov; 8(11):1020-7. PubMed ID: 12424715 [Abstract] [Full Text] [Related]
11. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation. Zou WL, Zang YJ, Chen XG, Shen ZY. Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848 [Abstract] [Full Text] [Related]
14. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S. Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001 [Abstract] [Full Text] [Related]
15. Liver transplantation results for hepatocellular carcinoma in Chile. Gabrielli M, Vivanco M, Hepp J, Martínez J, Pérez R, Guerra J, Arrese M, Figueroa E, Soza A, Yáñes R, Humeres R, Rios H, Palacios JM, Zapata R, Sanhueza E, Contreras J, Rencoret G, Rossi R, Jarufe N. Transplant Proc; 2010 Jun; 42(1):299-301. PubMed ID: 20172336 [Abstract] [Full Text] [Related]
16. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Nocera A, Andorno E, Tagliamacco A, Morelli N, Bottino G, Ravazzoni F, Casaccia M, Barocci S, Alice S, Santori G, Ghirelli R, Valente U. Transplant Proc; 2008 Jun; 40(6):1950-2. PubMed ID: 18675098 [Abstract] [Full Text] [Related]
17. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW. Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207 [Abstract] [Full Text] [Related]
18. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW. Liver Transpl; 2004 Dec; 10(12):1478-86. PubMed ID: 15558585 [Abstract] [Full Text] [Related]